The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have either have breast cancer HER2+ Breast Cancer or Triple Negative Breast Cancer (TNBC) which is in an advanced stage and has metastasized to your brain. The purpose of this study is to test any good and bad effects of the study drug called Dendritic cell vaccines (DC1) and pembrolizumab.
You will be on active treatment for approximately 2 years. During the first portion (Initial Treatment Phase), you will be treated with the Dendritic cell vaccine and pembrolizumab every three weeks. You will then be treated with pembrolizumab as a maintenance treatment. Once you have finished your treatment you will be contacted by phone every 6 months for 2 years by the research coordinator.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04348747